Recent News

• 04.23.2025 - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
• 04.23.2025 - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
• 04.21.2025 - Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
• 03.25.2025 - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
• 03.25.2025 - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
• 03.03.2025 - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
• 12.17.2024 - Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
• 12.17.2024 - Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
• 12.09.2024 - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
• 12.09.2024 - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Recent Filings

• 04.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.21.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.17.2024 - EX-99.1 EX-99.1
• 12.17.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]